Follow us...


Search News Archives

News Channels


Coronavirus (COVID-19)


View Channel

New Laboratory Products


View Channel

Lab News


View Channel

Research & Case Studies


View Channel

Microscopy | Image Analysis


View Channel

Separation Science


View Channel



View Channel

Events | Webinars


View Channel

Conferences | Events

BD Medical Pharmaceutical Systems confirms product performance using Nanoparticle Tracking Analysis

Silicone oil is commonly used as a lubricant coating in prefilled syringes (PFS) and is becoming one of the most highly discussed topics in the PFS market, particularly for developers of highly sensitive biotech drugs.

BD Medical In specific biological drug cases, unexpected drug-container interactions have been reported that were potentially attributed to or potentially associated with sub-visible particles generated from the lubricating silicone layer. These could lead to “solution inspection” concerns or even compatibility concern. Sebastien Jouffray is Core Team leader in the R&D Product Development Group at BD Medical – Pharmaceutical Systems. He leads a team working on an innovative immobilised silicone coating, (XSi™). BD XSi™ significantly reduces sub-visible particles (SbVPs) while retaining lubrication performance. BD XSi™ does not introduce any new materials, enabling rapid implementation in PFS for both legacy as well as pipeline drugs.

Detection of SbVPs, defined as particles that cannot be reliably detected by visual inspection with unaided human eye, is continuously being improved by emerging analytical techniques. In particular, the extension of the SbVP size detection limit below 10 μm, potentially into the sub-micron range, and the ability to differentiate the nature of those particles will greatly enhance the potential to monitor and report this critical attribute. Such analytical techniques can be used to understand better the contribution of silicone lubricant in prefilled syringes, to the overall pool of detected SbVPs. This knowledge will be critical to monitor, control and, if a specific need arises, reduce this contribution.

This need led Jouffray to add new techniques to his arsenal of characterization tools. He used Nanoparticle Tracking Analysis from NanoSight to clearly show that their new coating, BD XSi™, radically reduced the presence of particles compared with traditional baked silicone and conventional sprayed-silicone prefilled syringes. This data, reported in a focus on injectable drug delivery by ONdrugDELIVERY1, clearly demonstrated that BD XSi™ provides a true reduction in particles in both micron and sub-micron ranges and not just a shift in counts from one range to another.

Noting the benefits of using NanoSight’s NTA instrumentation in complement to other characterization techniques, Jouffray said “NanoSight allows for the counting of nano-sized particles in small sample volumes in parallel with other techniques. This gives us cost effective routine characterization technique verifying the quality of BD Neopak XSi™ and for pharmaceutical companies a new technology to count SbVPs in nano range scale”

more about BD XSi

more about BD Medical - Pharmaceutical System

more about Nanosight

more news from Nanosight


If you have not logged into the website then please enter your details below.



Popular this Month...

Our Top 10 most popular articles this month


Today's Picks...




Looking for a Supplier?

Search by company or by product


Company Name:




Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd




Media Partners